Original Article
  

Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice

Influenza Adjuvanted-vaccine

Abstract

Utilizing subunit vaccines is one of the strategies to address influenza infection. Recent innovations have focused on high doses of vaccine antigens and immune enhancers or adjuvant to induce more robust and long-lasting immune responses. Here, an effect of the B cell-activating factor receptor (BAFF-R) to increase the magnitude and durability of immune responses of the recombinant HA1 (rHA1) protein against the H1N1 influenza virus was studied.
The HA1 protein and the effector domain of BAFF-R were expressed in the pET-28a (+) vector. Eight-week-old BALB/c mice were equally grouped into five groups (n=20). The 15 and 25 μg/μL of rHA1 were mixed with 2 μg/μL of rBAFF-R and injected three times for vaccinated groups. Three control groups were received normal saline and two concentrations of rHA1. The ability of rBAFF-R in eliciting HA-specific antibody response and stimulating T lymphocyte proliferation to induce the cell-mediated immunity was assayed. Induction of protection was evaluated following the challenge with PR8 strain.
Analysis of immune responses showed that the co-administration of rBAFF-R with rHA1 boosted HI responses to the antigen in mice, whilst it was not able to promote the T cell proliferation responses against influenza. Compared to rHA1alone, the rBAFF-R/rHA1 generated efficient protection for the animals. There were no significant differences in eliciting the immune responses in mice immunized with the lower dose of rHA1 than that with the higher dose.
The data indicate the rBAFF-R can enhance the primary and memory immune responses to protect against influenza infection.

1. Bai L, Zhao Y, Dong J, Liang S, Guo M, LiuX, et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31(3):395–403.
2. Cuadrado-Payán E, Montagud-Marrah M, Torres-Elorza M, Bodro M, Blasco M, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020;6736(20):31052-7.
3. Padilla-QuirarteHO, Lopez-Guerrero DV, Gutierrez-Xicotencat L, Esquivel-Guadarrama F. Protective antibodies against influenza proteins. Front Immunol. 2019;10:1677.
4. Watanabe A, McCarthy KR, Kuraoka M, Schmidt AG, Adachi Y, Onodera T, et al. Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism. Cell. 2019;177(5):1124-35.
5. Mallajosyulaa VVA, Citronb M, Ferrarac F, Lub X, Callahanb C, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. PNAS. 2014; 111(21):13133-8.
6. Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19(3):383–97.
7. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
8. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm. 2015;94(9):251-63.
9. Fox, CB, Kramer, RM, Barnes, L, Dowling, QM, Vedvick, TS. Working together: interactions between vaccine antigens and adjutants. Ther Adv Vaccines. 2013;1(1):7-20.
10. Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, et al. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol. 2010;84(24):12703-12.
11. Soleimani S, Shahsavandi S, Madadgar O. Improvement influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant. Biologicals. 2017;46(3):6-10.
12. Dehghan A, Shahsavandi S, Jabalameli L. Improvement efficacy of influenza nanovaccine in combination with hemokinin-1 molecular adjuvant. Avicenna J Med Biotechnol. 2018;10(4):208-13.
13. Thompson AL, Staats HF. Cytokines: The future of intranasal vaccine adjuvants. Clin Dev Immunol. 2011;2011:289597.
14. Nga, LG, Macka, CR, Mackay, F. The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 2015;42(7):763-72.
15. Rodig, SJ, Shahsafaei, A, Li, B, Dorfmana DM. BAFF-R, the major B cell–activating factor receptor, is expressed on most mature B cells and B-cell lympho proliferative disorders. Human Pathol. 2005;36(10):1113-9.
16. Smulski CR, Eibel H. BAFF and BAFF-Receptor in B cell selection and survival. Front Immunol. 2018;9:2285.
17. Karpusas, M, Cachero, TG, Qian, F, Boriack-Sjodin, A, Mullen, C, et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol. 2002;315(5):1145-54.
18. Zhang, F, Song, SS, Shu, JL, Li, Y, Wu, YJ, et al. BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor. Acta Pharmacol Sin. 2016;37(8):1101-9.
19. Rolink, AG, Tschopp, J, Schneider, P, Melchers, F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002;32(7):2004-10.
20. Guan, NGL, Sutherland, APR, Newton, R, Qian, F, Cachero, TG, et al. B Cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807-17.
21. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Global Influenza Surveillance Network. World Health Organization.2011. https://apps.who.int/iris/handle/10665/44518.
22. Angeletti D, Kosik I, Santos JJS, Yewdell WT, Boudreau CM, Mallajosyula VVA, et al. Outflanking immunodominance to target subdominant broadly neutralizing epitopes. PNAS. 2019;116(27):13474-9.
23. Nicholls EF, Madera L, Hancock RE. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci. 2010;1213(23):46-61.
24. Waithman, J, Mintern, JD. Dendritic cells and influenza A virus infection. Virulence. 2012;3(1):603-8.
25. Allenspach, EJ, Lemos, MP, Porrett, PM, Turka, LA, Laufer, TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity. 2008;29(5):795-806.
26. Steel J, Lowen A, Wang TT, Yondola M, Gao Q, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 2010;1:e00018-10.
Files
IssueVol 21 No 2 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijaai.v21i2.9228
Keywords
B cell-activating factor receptor Hemagglutinins Immunity Influenza A virus H1N1 subtype
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Bagheri Yazdi SM, Shahsavandi S, Fotouhi F, Tebianian M, Ebrahimi MM. Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice. Iran J Allergy Asthma Immunol. 2022;21(2):207-214.